3HP preventive treatment among children and adolescents with HIV and child household contacts of TB patients
INTRODUCTION: India’s National TB Elimination Programme plans to roll out short-course TB preventive therapy (TPT) using 3 months of rifapentine and isoniazid (3HP). Understanding the feasibility and safety of children in programmatic settings is critical for widespread implementation. We present th...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
International Union Against Tuberculosis and Lung Disease (The Union)
2024-09-01
|
| Series: | IJTLD Open |
| Subjects: | |
| Online Access: | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000009/art00007 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591392121028608 |
|---|---|
| author | A. Kinikar R. Borse B. Randive P. Kamath S.K. Mattoo M. Parmar H. Solanki V. Mave A. Gupta R.E. Chaisson N. Suryavanshi |
| author_facet | A. Kinikar R. Borse B. Randive P. Kamath S.K. Mattoo M. Parmar H. Solanki V. Mave A. Gupta R.E. Chaisson N. Suryavanshi |
| author_sort | A. Kinikar |
| collection | DOAJ |
| description | INTRODUCTION: India’s National TB Elimination Programme plans to roll out short-course TB preventive therapy (TPT) using 3 months of rifapentine and isoniazid (3HP). Understanding the feasibility and safety of children in programmatic settings is critical for widespread implementation. We present the findings of a targeted scale-up of 3HP among children and adolescents living with HIV (CALHIV) and child household contacts (>2 to <6 years) of pulmonary TB patients (CHHC). METHODS: Between December 2021 and July 2023, eligible CALHIV and CHHC participants were given weekly dosages of 3HP for 3 months at antiretroviral therapy (ART) and TB clinics, respectively, of a public hospital in Pune, India. RESULTS: Of 97 children screened, 91 initiated 3HP (32 CALHIV and 59 CHHC). The median age of CALHIV was 14 years; 66% were male and on dolutegravir-based ART. The median age of CHHC was 4 years; 47% were males. Thirty-one (97%) CALHIV and 56 (95%) CHHC completed 3HP without dolutegravir dose adjustment. None of the child participants discontinued 3HP due to adverse events. No child participant developed TB during 1 year of follow-up post-3HP. CONCLUSION: Our study provides evidence of the uptake and feasibility of the planned nationwide rollout of 3HP. |
| format | Article |
| id | doaj-art-a8fd949e2d854c68b429d02b65f31241 |
| institution | Kabale University |
| issn | 3005-7590 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | International Union Against Tuberculosis and Lung Disease (The Union) |
| record_format | Article |
| series | IJTLD Open |
| spelling | doaj-art-a8fd949e2d854c68b429d02b65f312412025-01-22T12:16:08ZengInternational Union Against Tuberculosis and Lung Disease (The Union)IJTLD Open3005-75902024-09-011941341710.5588/ijtldopen.24.030573HP preventive treatment among children and adolescents with HIV and child household contacts of TB patientsA. Kinikar0R. Borse1B. Randive2P. Kamath3S.K. Mattoo4M. Parmar5H. Solanki6V. Mave7A. Gupta8R.E. Chaisson9N. Suryavanshi10Byramjee Jeejeebhoy Government Medical College (BJGMC), Pune, India;Byramjee Jeejeebhoy Government Medical College (BJGMC), Pune, India;BJGMC–Johns Hopkins University Clinical Research Site, Pune, India;Byramjee Jeejeebhoy Government Medical College (BJGMC), Pune, India;Central Tuberculosis Division, New Delhi, India;World Health Organisation, Country office for India, New Delhi, India;World Health Organisation, Country office for India, New Delhi, India;BJGMC–Johns Hopkins University Clinical Research Site, Pune, India;Johns Hopkins University, School of Medicine, Baltimore, MD, USA.Johns Hopkins University, School of Medicine, Baltimore, MD, USA.BJGMC–Johns Hopkins University Clinical Research Site, Pune, India;INTRODUCTION: India’s National TB Elimination Programme plans to roll out short-course TB preventive therapy (TPT) using 3 months of rifapentine and isoniazid (3HP). Understanding the feasibility and safety of children in programmatic settings is critical for widespread implementation. We present the findings of a targeted scale-up of 3HP among children and adolescents living with HIV (CALHIV) and child household contacts (>2 to <6 years) of pulmonary TB patients (CHHC). METHODS: Between December 2021 and July 2023, eligible CALHIV and CHHC participants were given weekly dosages of 3HP for 3 months at antiretroviral therapy (ART) and TB clinics, respectively, of a public hospital in Pune, India. RESULTS: Of 97 children screened, 91 initiated 3HP (32 CALHIV and 59 CHHC). The median age of CALHIV was 14 years; 66% were male and on dolutegravir-based ART. The median age of CHHC was 4 years; 47% were males. Thirty-one (97%) CALHIV and 56 (95%) CHHC completed 3HP without dolutegravir dose adjustment. None of the child participants discontinued 3HP due to adverse events. No child participant developed TB during 1 year of follow-up post-3HP. CONCLUSION: Our study provides evidence of the uptake and feasibility of the planned nationwide rollout of 3HP.https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000009/art00007tuberculosispaediatric tbtb preventive treatmentchildren and adolescentshiv |
| spellingShingle | A. Kinikar R. Borse B. Randive P. Kamath S.K. Mattoo M. Parmar H. Solanki V. Mave A. Gupta R.E. Chaisson N. Suryavanshi 3HP preventive treatment among children and adolescents with HIV and child household contacts of TB patients IJTLD Open tuberculosis paediatric tb tb preventive treatment children and adolescents hiv |
| title | 3HP preventive treatment among children and adolescents with HIV and child household contacts of TB patients |
| title_full | 3HP preventive treatment among children and adolescents with HIV and child household contacts of TB patients |
| title_fullStr | 3HP preventive treatment among children and adolescents with HIV and child household contacts of TB patients |
| title_full_unstemmed | 3HP preventive treatment among children and adolescents with HIV and child household contacts of TB patients |
| title_short | 3HP preventive treatment among children and adolescents with HIV and child household contacts of TB patients |
| title_sort | 3hp preventive treatment among children and adolescents with hiv and child household contacts of tb patients |
| topic | tuberculosis paediatric tb tb preventive treatment children and adolescents hiv |
| url | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000009/art00007 |
| work_keys_str_mv | AT akinikar 3hppreventivetreatmentamongchildrenandadolescentswithhivandchildhouseholdcontactsoftbpatients AT rborse 3hppreventivetreatmentamongchildrenandadolescentswithhivandchildhouseholdcontactsoftbpatients AT brandive 3hppreventivetreatmentamongchildrenandadolescentswithhivandchildhouseholdcontactsoftbpatients AT pkamath 3hppreventivetreatmentamongchildrenandadolescentswithhivandchildhouseholdcontactsoftbpatients AT skmattoo 3hppreventivetreatmentamongchildrenandadolescentswithhivandchildhouseholdcontactsoftbpatients AT mparmar 3hppreventivetreatmentamongchildrenandadolescentswithhivandchildhouseholdcontactsoftbpatients AT hsolanki 3hppreventivetreatmentamongchildrenandadolescentswithhivandchildhouseholdcontactsoftbpatients AT vmave 3hppreventivetreatmentamongchildrenandadolescentswithhivandchildhouseholdcontactsoftbpatients AT agupta 3hppreventivetreatmentamongchildrenandadolescentswithhivandchildhouseholdcontactsoftbpatients AT rechaisson 3hppreventivetreatmentamongchildrenandadolescentswithhivandchildhouseholdcontactsoftbpatients AT nsuryavanshi 3hppreventivetreatmentamongchildrenandadolescentswithhivandchildhouseholdcontactsoftbpatients |